Skip to Main Content

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors

Conditions

Phase I

Phase I

What is the purpose of this trial?

This research study is studying a new drug, NC762, as a possible treatment for advanced or metastatic solid tumors.

  • Trial with
    NextCure, Inc.
  • Start Date
    07/08/2022
  • End Date
    10/01/2024

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    07/12/2022
  • Study HIC
    #2000030669